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INTRODUCTION
Atopic dermatitis (AD) is a chronic relapsing, severely prurit-
ic, eczematous skin disease that may be accompanied by other 
allergic diseases, such as asthma and allergic rhinitis. The inci-
dence of AD has steadily increased, with an estimated preva-
lence of 15%-0% in children and 1%-3% in adults.1,2 The symp-
toms of AD may appear in as early as infancy, which markedly 
improve or clear before or during adolescence in about 30%-
50% of the patients. The persistence of AD until adulthood is in-
creasing, reaching up to 60%, and shows a more chronic and 
recurrent course, causing a significant social burden.3
Clinical features of AD are diverse, and this heterogeneity may 
be due to the multifactorial pathogenesis of the disease, in 
which defects of the skin barrier, environmental factors, and 
immunological dysregulation are involved.4,5 Immune dysregu-
lation of cytokine imbalance with increased Th2 and Th22 
skewing has been emphasized as a crucial pathogenesis that 
results in the disruption of keratinocytes.6 The primary disrup-
tion of the skin barrier, on the other hand, due to filaggrin mu-
tation is also considered significant, allowing increased pene-
tration of allergens and microbes, enhancing Th2 polarization-
through dendritic cells. Due to such complicated mechanisms 
of pathogenesis, clinical features of patients with AD are com-
plex and may differ even within the same age group.7 This was a 
prospectively designed, retrospectively analyzed study, in 
which we reviewed various clinical features and different sub-
types of AD to better understand the clinical diversity of AD in 
Korea and help physicians treat their patients.
MATERIALS AND METHODS
Patients
We reviewed the medical records and laboratory data of 5,000 
patients who initially visited the outpatient clinic at the depart-
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ment of dermatology and was diagnosed with AD between Oc-
tober 2007 and January 2015. The diagnosis of AD was made 
according to the diagnostic features of Korean diagnostic crite-
ria for AD,9 which were established on the basis on the guide-
lines of Hanifin and Rajka.8 The symptom severity was assessed 
by using the eczema area and severity index (EASI) score at the 
initial visit.10 Mild severity was defined as an EASI score of <7, 
moderate severity as ≥7 and <21, and severe AD as ≥21.11 The 
patients were divided into those with intrinsic and extrinsic 
types of AD. The intrinsic type was defined as a total IgE of 
<150 kU/L and no sensitization to allergens as confirmed by 
ImmunoCAPassay (Phadia, Uppsala, Sweden), whereas the ex-
trinsic type was defined as a total IgE of >150 kU/L or positive 
sensitization in the CAP immunoassay.12,13 The total IgE levels 
were assessed, in which the maximum measurable value was 
5,000 kU/L. Thus, patients with higher values were regarded as 
having 5,000 kU/L.
Questionnaire
At their initial visits, the patients were given a questionnaire 
that included information about the onset of AD; their medical 
histories of atopic diseases including allergic rhinitis, allergic 
conjunctivitis, and allergic asthma; family histories of atopic 
diseases; the factors that aggravated their symptoms; and the 
past treatments that they had received. For the aggravating fac-
tors, a specific list was given, which included seasonal varia-
tions, sweating, stress, food, and clothing (the entire list can be 
seen in Results).
Laboratory tests
At initial visits, blood tests were performed including com-
plete blood count; routine chemistry; serum total IgE; and sen-
sitization to specific allergens related to AD which include 
house dust mites (Dermatophagoidesfarina [D. farinae], Der-
matophagoidespteronyssinus [D. pteronyssinus]), egg white, 
milk, flour, peanut, bean, pork, and cockroach, as detected with 
CAP immunoassay. Patients were considered sensitized to the 
allergens when the results of CAP immunoassay were greater 
than or equal to class 3 (≥3.5 kU/L).
Statistical analysis
Data are presented as mean±standard deviation (SD). The 
results were analyzed by using Student’s t tests, 1-way analysis 
of variance, and χ2 tests. Deviations were considered statistical-
ly significant when P<0.05. SPSS version 19.0 (SPSS Inc., Chica-
go, IL, USA) was used for all statistical analyses.
RESULTS
Demographics of the patients
Table 1 shows the demographics of the patients. There was no 
difference in the male-to-female ratio (M/F, 52:48), and the 
mean age of the patients was 18.99±10.22 years at the initial 
visit. Their ages ranged from early infancy to 86 years, with a 
predominance of adult patients >19 years old (51.1%). Most of 
the patients had an onset age of <18 years; those with onset 
during infancy (≤2 years old) was 28.0%, and those with onset 
during childhood and adolescence were 49.0%. A relatively 
high percentage (22.0%) of the patients developed AD after 
adulthood. The geographic data of the patients were also ana-
lyzed; most of the patients were from Seoul (57.1%), the capital 
of Korea,where our hospital is located. The patients came from 
all areas of Korea.Of the 5,000 patients, 0.4% came from Ulsan 
and 26.7% came from Gyeonggiprovince.
Allergic comorbidities and family history of allergic diseases
Allergic march is a feature ofAD, and the presence of allergic 
comorbidities, which include allergic rhinitis, allergic asthma, 
and allergic conjunctivitis, was assessed (Table 2). In our data, 
34.3% of the AD patients had allergic comorbidities, with 78.3% 
having a single comorbidityand the rest (21.7%) having multi-
ple comorbid atopic diseases. Of the patients with a single aller-
gic comorbidity, allergic rhinitis was the most common (82.0%), 
followed by allergic conjunctivitis (10.9%) and allergic asthma 
(7.1%). The proportion of patients with any family history of at-
opy was 30.2%, with allergic rhinitis (61.6%) also being the most 
common, followed by AD (47.5%), allergic asthma (10.1%), and 
allergic conjunctivitis (3.8%).
Allergic sensitization
Fig. 1 shows that 3,815 (76.3%) of the patients were classified 
as the extrinsic type, whereas the rest (1,185, 23.7%) were classi-
fied as the intrinsic type. The 2 types were further categorized 
Table 1. Number of patients (%) by sex, age at the initial visit, and age of onset
Number of patients (%)
Gender
   Male 2,590 (51.8)
   Female 2,410 (48.2)
Age (at initial visit)
   0-2 yr 205 (4.1)
   3-10 yr 1,040 (20.8)
   11-18 yr 1,200 (24.0)
   19-30 yr 1,885 (37.7)
   31-40 yr 540 (10.8)
   41-50 yr 85 (1.7)
   > 50 yr 45 (0.9)
Age of onset
   <1 yr 749 (15.0)
   1-2 yr 652 (13.0)
   3-6 yr 955 (19.1)
   7-18 yr 1,498 (30.0)
   >18 yr 1,146 (22.9)
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by age, and it was found that there were almost equal numbers 
of patients in infancy with the extrinsic vs intrinsic type (50.8% 
vs 49.2%) and that as the age increased, the proportion of pa-
tients with the extrinsic type, who are more sensitized to aller-
gens, gradually increased up to 80.5% of adult AD patients. Sen-
sitization to specific allergens was detected by using CAP im-
munoassay (Fig. 2), and of the several allergens tested, D. fari-
nae (59.7%) and D. pteronyssinus (59.5%) were found to have 
the highest sensitization rates. The level of total IgE was in-
creased in most of the patients, with an average of 1,319.35±
1,609.77 kU/L.
AD diagnostic features and variable clinical phenotypes
The percentage of each feature fulfilled in the Korean diagnos-
tic criteria for AD was assessed. Of the major features, pruritus 
was observed in all the patients; of the minor features, xerosis 
was most common, followed by pruritus with sweating (Fig. 3). 
The affected areas of the body were evaluated (Fig. 4), and 
symptoms that were dispersed throughout the whole body 
were found in 46% of the patients. The head and neck area was 
involved in 35% of the patients, followed by the upper extremi-
ties (33%), lower extremities (25%), and trunk (16%). These 
data differ among different age groups: infants and adults 
showed involvements in their head and neck area the most 
(25.3% and 23.9%, respectfully), whereasin patients in their 
childhood (ages 2-12 years),the upper extremities were the 
most involved body part (22.6%). The proportion of different 
clinical subtypes that presented with AD was also assessed.Pa-
tients who accompanied the nummular eczema type were 
found to be 7.65%, followed by those with the prurigo type 
(2.78%), red face (1.15%), and lichen amyloidosis (0.51%). In 
addition, 5.61% of the patients were found to have eczema her-
peticum.
To assess the severity of AD, the EASI score was used, and the 
average EASI score was found to be 13.68 (±10.22). The pro-
portion of patients with mild severity was 28.2%, those with 
Table 2. Number of patients with a family history of allergic diseases and co-
morbid atopic diseases
History Number of patients (%)
Family history
   Positive family history 1,510 (30.2)
   AD 717 (47.5)
   AR 930 (61.6)
   AA 153 (10.1)
   AC 57 (3.8)
History of atopic diseases
   Presence of comorbid allergic disease 1,715 (34.3)
   Single comorbid allergic disease 1,343 (78.3)
   AR 1,101 (82.0)
   AC 146 (10.9)
   AA 95 (7.1)
   Multiple comorbid allergic diseases 372 (21.7)
   AR+AA 163 (43.7)
   AR+AC 165 (44.4)
   AA+AC 6 (1.6)
   AC+AA+AR 38 (10.3)
AD, atopic dermatitis; AR, allergic rhinitis; AA, allergic asthma; AC, allergic 
conjunctivitis.
Fig. 1. The proportion of extrinsic and intrinsic types according to different age 
groups. The age groups were defined as follows: infancy ≤2 years old, child-
hood and adolescence >2 years old and ≤18 years old, and adulthood>18 
years old. The intrinsic type was defined as a total IgE of <150 kU/L and with 
no sensitization to allergens, whereas the extrinsic type was defined as a total 
IgE of >150 kU/L or a positive sensitization in CAP immunoassay.
Fig. 2. Evaluation of sensitization to specific allergens in CAP immunoassay. D. 
pteronyssinus, Dermatophagoidespteronyssinus; D. farinae, Dermatophagoi-
desfarinae.
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Minor features
1. Pruritus
2. Typical distribution
    1) <2 years: face, trunk, extensor surface
    2) >2 years: face, neck, flexural area
3. PHx of FHx of atopic diseases (atopic dermatitis, asthma, allegic rhinitis)
Fig. 3. The percentages of each fulfilled criterion of the (A) major features and (B) minor features of the diagnostic criteria. PHx, past history; FHx, family history.
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Minor features
1. Xerosis
2. Pityriasis alba
3.  Periorbital eczema and 
hyperpigmentation
4. Periauricular eczema
5. Cheilitis
6. Nonspecific hand/foot dermatitis
7. Scales on the scalp
8. Perifollicular accentuation
9. Nipple eczema
10. Pruritus when sweating
11.  White dermographism
12. Positive skin prick test
13. High titer of serum total IgE
14. Susceptibility to skin infection
Fig. 4. Proportion of the involved parts of the body according to different age groups.The age groups are defined as follows: infancy ≤2 years old, childhood and ad-
olescence >2 years old and ≤18 years old, adulthood >18 years old.
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moderate severity 42.8%, and those with severe severity 29.0%. 
Further stratifying the EASI score according to different age 
groups, patients in their infancy (age≤2 years) were mostly 
found to have either mild or moderate symptoms (90.4%, 
EASI<21), and as the age of the patients increased, the severity 
score increased, with 34.10% of the patients in their adoles-
cence or adulthood classified as having severe AD (Fig. 5A). In 
addition, patients who had AD that persisted until adulthood 
and those with pure adult-onset AD were compared (Fig. 5B). 
Adult patients with AD onset before adulthood had an average 
EASI score of 17.04 (±13.93), whereas those with adult-onset 
AD had a score of 14.59 (±12.41), and the difference was statis-
tically significant (P<0.01).
The EASI scores were also compared between male and fe-
male patients (Fig. 6A). The mean EASI score was 16.47 (±
12.66) in male patients and 12.69 (±11.11) in female patients, 
and the difference was statistically significant (P<0.001). The 
relationship between sex and severity was further stratified and 
analyzed (Table 3). In the group with mild severity, 40.4% were 
male patients and 59.6% were female patients. The proportion 
of male patients increased with increased severity. For moder-
ate severity, the proportions of male and female patients were 
Fig. 5. Association of severity and age. (A) The patients of different age groups stratified by EASI scores into mild, moderate, and severe groups. (B) The differences 
of EASI scores between adult patients with onset before adulthood and those with adultonset. The age groups were defined as follows: infancy ≤2 years old, child-
hood and adolescence >2 years old and ≤18 years old, and adulthood >18 years old.The EASI scores ranged from 0 to 72, with the scores stratified as follows: 
mild <7, moderate ≥7 and <21, and severe ≥21. EASI, eczema area and severity index. *P<0.01.
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53.9% and 46.1%, respectively, and there were 62.2% males and 
37.8% females in the severe group. The differences in the preva-
lence of the patients of different sexes between individual se-
verity groups were statistically significant (P<0.001). The rela-
tionship between the total IgE levels and EASI scores were as-
sessed (Fig. 6B). The mean total IgE level of the group with mild 
severity was 694.08 kU/L. The mean total IgE levels of the mod-
erate and severe groups were 1,319.81 and 2,612.27 kU/L, re-
spectively, and the differences between the 3 groups were sta-
tistically significant (P<0.001).
Aggravating factors
Aggravating factors were assessed by using a survey (Fig. 7A). 
For the 25 factors surveyed, 3,951 (79%) patients selected sea-
sonal changes as the aggravating factor that affected their 
symptoms the most, followed by stress (2,998, 60%), dryness 
(2,550, 51%), and sweating (1,847, 37%). For months during 
which the symptoms were most severe were also assessed (Fig. 
7B), 2,335 and 2,421 patients responded that as the months 
when their symptoms were worst July and August (46.7% and 
48.4%, respectively), followed by December (2,208, 44.2%) and 
January (1,785, 35.7%). The month during which the symptoms 
were least severe was May, as reported by 821 (16.4%) patients.
Treatment experience
The patients were also questioned on all treatment methods 
that had been used before their visit to our clinic. Diverse treat-
ments have been attempted, and topical steroids were the most 
commonly used treatment (70.9%) added on moisturizers used 
by 85.8% of the patients. Of the patients, 46.7% reported trying 
folk remedies (Fig. 8A).
At our clinic, the most frequently prescribed medication was 
Table 3. Comparison of the number of male and female patients in each sever-
ity group
Males Females P value
Mild 612 (40.4%) 901 (59.6%) <0.001
Moderate 1,237 (53.9%) 1,059 (46.1%) <0.001
Severe 740 (62.2%) 450 (37.8%) <0.001
The groups were subdivided according to the following eczema area and sever-
ity index scores: mild <7, moderate ≥7 and <21, and severe ≥21. Chi-
square test was performed to confirm the significance of the differences be-
tween the 2 groups.
Fig. 7. (A) Aggravating factors. (B) Aggravation of symptoms according to months of the year assessed by using a questionnaire.
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topical steroids (60.9%), followed by low-dose oral cyclosporine 
(56.7%). Oral steroids were not commonly used (25.8%) and 
only prescribed during acute exacerbations. Topical calcineurin 
inhibitors were used in 17.5% of the patients, and allergen-spe-
cific immunotherapy was done in 10.1% of the patients (Fig. 8B).
DISCUSSION
AD has been known to have no sex difference in prevalence 
until the age of 6 years; thereafter, the number of female pa-
tients becomes slightly higher than that of male patients.1 In our 
study, no difference in prevalence was found between the sexes 
(M/F, 52:48). The percentage of patients aged >18 years at the 
initial visit was 51.1%, with a mean age of 18.99 years. Com-
pared with previous epidemiologic studies of AD, this relatively 
older age group can be attributed to the fact that the data were 
obtained from a clinic in a tertiary hospital, where patients with 
a more chronic course that persists until adulthood would be 
more likely to visit. In terms of geographic data, although most 
of the patients were from Seoul (57.1%), the capital city and also 
where our hospital is located, the remaining 42.9% of the pa-
tients were from all the other cities. The higher number of pa-
tients from Seoul may be due to the location of our hospital, but 
the fact that the population is higher in larger urban cities may 
have contributed to the results.14
A positive family history of allergic diseases was found in 
30.2% of the patients in our study. Of the allergic diseases, aller-
gic rhinitis was the common (61.6%), followed by AD (47.5%). 
Family history, one of the major criteria in the diagnosis of AD, 
is known to be an important risk factor for AD. Studies from 
Western countries have found a positive family history of atopy 
in 53%-80% of patients.15,16 In a recent study in Korean children 
with AD, about 40% had a family history,17 whereas a few others 
have shown a positive family history in 28% and 47.8%.15,18 In a 
study on adult-onset AD, 54.2% had a family history with most 
cases having allergic rhinitis.19 Patients with a family history of 
atopy were fewer in our study than in previous studies. Howev-
er, the results are diverse, and further studies are needed to de-
Fig. 8. List of the treatments that the patients have received (A) in the past and (B) at our clinic.
N
um
be
r o
f p
at
ie
nt
s (
%
)
N
um
be
r o
f p
at
ie
nt
s (
%
)
Types of treatments
Types of treatments
Topical steroid Topical calcineurin
inhibitor
Oral steroid Cyclosporine Immunotherapy Others
100
80
60
40
20
0
70
60
50
40
30
20
10
0
A
B
85.8
(4,290)
60.9
(3,045)
70.9
(3,545)
17.5
(875)
30.6
(1,530)
25.8
(1,290)
27.7
(1,385)
5.8
(290)
56.7
(2,835)
4.8
(240)
10.1
(505)
0.4
(20)
9.5
(475) 1.3
(65)
46.7
(2,380)
6.3
(315)
0.5
(25)
Em
olli
en
t
Top
ica
l st
ero
id
Or
al s
ter
oid
Or
al a
nti
his
tam
ine
Top
ica
l ca
lcin
eu
rin
 inh
ibit
or
Or
al i
mm
un
om
od
ula
tor
De
se
ns
itiz
ati
on
Ph
oto
the
rap
y
Es
se
nti
al f
att
y a
cid
Fo
lk r
em
ed
y
Oth
ers
Review of 5,000 Patients With Atopic Dermatitis
Allergy Asthma Immunol Res. 2017 March;9(2):158-168. https://doi.org/10.4168/aair.2017.9.2.158
AAIR
http://e-aair.org  165
termine whether this discrepancy is due to different ethnicities, 
age groups, or other undetermined factors.
CAP immunoassay was performed to evaluate the presence 
of sensitization to specific allergens, and D. farinae (59.7%), and 
D. pteronyssinus (59.5%) were found to be the allergens to 
which most patients were sensitized. House dust mites have 
been considered the major allergen related to AD, and the pro-
portion of sensitization to house dust mites in AD patients was 
similar to those reported by previous studies.20,21 In several 
studies, efforts have been made in reducing house dust mites; 
yet, no significant progress has been seen.22 In a recent study, D. 
pteronyssinus was found to be a major allergen for house dust 
mite-allergic AD patients, unlike in those with respiratory aller-
gy, suggesting the possibility of a useful serological marker.23 Al-
though more prominent in extrinsic types of AD, the total IgE 
levels were generally increased, with an average of 1,319.35±
1,609.77 kU/L found in our patients. In many previous reports, 
specific IgE or total serum IgE levels have been found to be sig-
nificantly associated with the severity of AD.24,25 Based on of 
these findings, measurement of the total IgE level is significant 
in patients with AD.
AD may be classified into 2 different types, extrinsic and in-
trinsic, which are also called allergic and non-allergic types. 
The intrinsic type, or non-allergic type, shows normal IgE levels 
in addition to the absence of any sensitization to allergens, 
whereas the extrinsic or allergic type has increased specific IgE 
levels with sensitization to specific allergens.13,26 Of patients 
with AD, 76.3% were found to havethe extrinsic types,whereas 
the rest (23.7%) had the intrinsic type. Our data seemed consis-
tent with those of previous reports: the incidence of extrinsic vs 
intrinsic AD in Germany (63% vs 37%),27 in Netherlands (78.2% 
vs 21.8%),28 and in Korea (80% vs 20%).29 Comparing the 2 types 
among different age groups, the proportion was similar be-
tween the extrinsic vs intrinsic type in the infancy group (age≤
2 years, 50.8% vs 49.2%), whereas the number of patients with 
the extrinsic type increased with age, reaching 80.5% in the ad-
olescent and adult groups (age >11 years). In previous reports, 
the intrinsic type was found to have a higher frequency in chil-
dren than inadults,30 with a 57% of intrinsic AD cases in infants31 
and an 87.5% of extrinsic AD cases in adults,26 which are similar 
to our data. Therefore, sensitization to allergens increases with 
age, leading to the increase in the proportion of the intrinsic 
types of AD. Moreover, our data are meaningful as they are con-
sistent with those of previous studies and have been confirmed 
in >5,000 patients.
Most of the patients had generalized eczematous lesions. The 
head and neck area was involved in 35% of the patients, fol-
lowed by the upper extremities (33%), lower extremities (25%), 
and trunk (16%). Patients in their infancy had the highest ten-
dency to have symptoms on the head and neck, whereas older 
children had more symptoms on the extremities, specifically in 
the flexural areas. The adults also had symptoms most com-
monly on the head and neck, followed by the upper extremities 
that included eczemas on the hands, being consistent with the 
result of previous studies.32 In our study, significantly lower vi-
tamin D levels were found in patients with AD, which was also 
most significantly related to eczema of the head and neck.33 
Further investigations are needed into the involvement of dif-
ferent anatomical sites according to different age groups, in 
which vitamin D levels may be one of theassociated factors.
In our study, the severity of AD was mainly assessed with the 
EASI score, and the average EASI score of our patients was 
13.68 (±10.22), corresponding to the moderate severity. Most 
of the infants had mild to moderate severity; however, the EASI 
score increased with age, reaching >30% of that of severe adult 
patients. As in previous studies, the severity was either mild or 
moderate in >80% of the infants and children,15,18 whereas a 
higher percentage (25%-31%) of patients in their adulthood 
had severe AD.7,34 Some other studies, however, showed contra-
dictory data, with only 1.7% of adult patients having severe 
AD.19 We also analyzed whether the disease severity differed 
between the adults with onset before adulthood and those with 
onset after adulthood. Those with earlier onsets had a statisti-
cally higher severity, which may indicate that those with symp-
toms persisting until adulthood may have more severe symp-
toms.
Further analyses concerning the severity of AD were per-
formed, and the association of sex with severity showed that 
male patients had significantly higher EASI scores than female 
patients. A previous study in the Korean population found a 
higher prevalence of male patients than in female patients.35 
Based on this study, the prevalence in each sex was additional-
ly analyzed by further subdividing the sex groups according to 
severity. As a result, more female patients belonged to the mild 
group, and the proportion of male patients increased with in-
creasing severity, with significant differences between sexes. 
Furthermore, the total IgE levels were assessed to determine 
their correlation with severity. The 3 groups stratified according 
to severity by using EASI scores showed that the increased EASI 
scores correlated with the total IgE levels. A study of 345 chil-
dren found that serum IgE levels correlated with the severity of 
AD as assessed according to the severity scoring of AD or the 
severity scoring of atopic dermatitis (SCORAD) index.36 Our 
study also proved the correlation of serum IgE levels with the 
severity of AD, which is a meaningful result as a large number 
of patients were analyzed.
Several morphological variants can be present in patients 
with AD, with the nummular eczema type being the most com-
mon (7.65%) in patients at our clinic. The onset of nummular 
eczema has been known to be mostly during adulthood, be-
tween ages 20 and 60 years, but it is also common in child-
hood.37 Its pathogenesis and relationship to AD is unclear; 
however, it appears to be the most common atypical type of 
AD, which represents almost about 50% of all types,7,19 consis-
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tent with the data from our patients. Prurigonodularis is also 
another variant that can be observed in patients with AD, and 
2.78% of the patients presented with the prurigo type. Although 
AD is a major cause, the mechanism of prurigo nodularis is un-
clear and the treatment may be challenging.38
Eczema herpeticum, or disseminated vesicular eruption 
caused by herpes simplex virus, was found in 5.61% of the pa-
tients. Because of the disruption of the skin barrier, AD patients 
are more susceptible to cutaneous viral infections, including 
eczema herpeticum. It affects approximately 3% of AD patients 
and may be fatal, causing keratoconjunctivitis, meningitis, and 
viremia, if untreated.39 Early onset, higher disease severity, 
greater Th2 polarization, impaired skin barrier, and sensitiza-
tion to multiple allergens are some factors associated with in-
creased susceptibility to eczema herpeticum.40 The higher per-
centage of patients with eczema herpeticum in our study may 
be because our facility is a tertiary hospital that is visited by pa-
tients with higher severity.
For numerous environmental factors that may affect the 
symptoms of AD, patients who visited our facility reported that 
seasonal changes, stress, dryness, and sweating were the fac-
tors aggravating their symptoms the most. This result probably 
contributes to the fact that AD patients are sensitive to environ-
mental conditions, and direct irritation to the skin, such as that 
caused by sweating or dryness, can easily aggravate the symp-
toms of AD. The patients reported that August (48%) is the 
month when their symptoms were worst, followed by July 
(47%), December (44%), and January and November (36%). In 
a previous study in the United Kingdom, hot weather and 
sweating were found to be the most common exacerbating fac-
tors,41 which can explain why the symptoms worsen during 
summer. In another study in Norway, however, the symptoms 
of AD improved after moving to a warm subtropical climate 
from a subarctic climate, which was explained by the effects of 
ultraviolet (UV) radiation from increased sunexposure.42 The 
same result was also observed in a study done in Italy, which 
can also be explained by the effects of increased sun exposure. 
The discrepancy in aggravation between summer or winter 
may be caused by the latitude and differences in the tempera-
ture, humidity, and climate of different regions.43 Likewise, 
summers in Korea are excessively humid with high tempera-
tures, which may lead to increased stress and thus aggravation 
of symptoms.
Patients with AD are frequently sensitized to house dust mites, 
and several recent, reports have shown that allergen-specific 
immunotherapy is a safe and efficacious treatment.44-46 At our 
facility, allergen-specific immunotherapy is recommended to 
patients with the extrinsic type of AD showing severe symp-
toms and experiencing frequent flare-ups, to those unrespon-
sive to conventional treatments, and to those who were able to 
regularly follow the schedules. Of the patients, 10.1% were on 
immunotherapy for at least 1 year unless remission was achieved. 
Immunotherapy was maintained for more than 3 years in re-
sponsive patients. Sensitization to house dust mites was con-
firmed in these patients, and allergen-specific immunotherapy 
was proved to be effective, with 92.7% of the patients showing 
improvement of pruritus and 45% of the patients achieving re-
mission. Only 16% of the patients showed either minimal im-
provement or no change.44,47 Its safety was also proved, with 
only 0.1% of systemic adverse effects, such as flu-like symp-
toms, observed in our institution. No fatal adverse events were 
reported, and other adverse effects were minimal, including ur-
ticaria or pruritus, and only seen in <1% of the patients.48 Al-
though the need for frequent visit and long treatment time may 
discourage patients to receive the therapy and lead to low com-
pliance,49 allergen-specific immunotherapy can be a useful op-
tion for refractory patients sensitized to house dust mites.
In the past, AD was generally considered a disease confined 
to infant-children-adolescent age groups. Recently, however, 
AD that progresses until adulthood and adult-onset AD have 
been steadily increasing. Most of the AD patients who had visit-
ed our clinic were adults,and we have demonstrated that these 
patientshave more severe symptoms, different anatomical dis-
tributions with increased involvement of the head and neck, 
and a higher proportion of the extrinsic type. Considering vari-
ous subtypes with diverse clinical features and different mani-
festations among different age groups of AD, treatment strate-
gies should be differentiated according to the age groups and 
subtypes in order to effectively treat patients.48 
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